At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 229 enrolled
Drug / intervention
FX006 +1 moredrug
Likely dose
FX006 3 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Parallel Group, Dose-Ranging Study Comparing FX006 to Commercially Available Triamcinolone Acetonide Injectable Suspension in Patients With Osteoarthritis of the Knee
In Brief
A Phase 2 clinical trial evaluating FX006 and TCA IR for Osteoarthritis of the Knee. Completed, enrolled 229 participants across 21 sites in 3 countries.
Detailed Summary
The purpose of this study was to evaluate the safety, efficacy and pharmacokinetics of FX006 in patients with osteoarthritis of the knee.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis of the Knee
CountriesAustralia, Canada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedDec 2011
Enrollment StartJun 2012
Primary CompletionApr 2013
TodayJul 2026
First PostedDec 7, 2011
Enrollment StartJun 1, 2012
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 14.6 years ago
Interventions
FX006drug
Single 3 mL intra-articular injection
TCA IRdrug
Single 1 mL intra-articular injection